WGRX Wellgistics Health Inc.

Subscribe to $WGRX

Wellgistics Health Inc.

Subscribe to $WGRX

$WGRX

Other Pharmaceuticals

Health Care

IPO Year: 2025

Exchange: NASDAQ

Recent Analyst Ratings for Wellgistics Health Inc.

Date	Price Target	Rating	Analyst

See more ratings

Wellgistics Health Inc. Press Releases

Fastest customizable press release news feed in the world

Wellgistics Health Annual Letter to Shareholders From the Office of the CEO March 2025
Dear Shareholders, TAMPA, FL, March 27, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health"), This time last year, Wellgistics was a private company, weathering the pressures of a broken pharmaceutical supply chain plagued with waste, inefficiencies, and a lack of pricing transparency that has decimated independent pharmacies and other stakeholders in the healthcare ecosystem. Today, we are a public company listed on the Nasdaq exchange under our new parent company name, Wellgistics Health, Inc. (NASDAQ:WGRX), we have completed several acquisitions that broaden our service offerings, and we have a full year 2024 pro forma consolidated net sales (assuming
3/27/25 8:05:00 AM ET
$WGRX
Other Pharmaceuticals
Health Care
Wellgistics Health Achieves SOC 2 Type 1 Compliance, Strengthening Security for AI-Driven Pharmacy Solutions and Employer-Based Healthcare Models
TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health"), a provider of pharmacy solutions and healthcare technology, has successfully completed a third-party audit and achieved SOC 2 Type 1 compliance. This milestone validates that Wellgistics Health meets the industry's highest standards for security, availability, processing integrity, confidentiality, and privacy, reinforcing its commitment to data protection and regulatory compliance. SOC 2 Type 1 certification, developed by the American Institute of Certified Public Accountants (AICPA), confirms that Wellgistics Health has implemented strong security controls and operational safegua
3/18/25 7:40:00 AM ET
$WGRX
Other Pharmaceuticals
Health Care
Wellgistics Health, Inc. Announces Leadership Transition: Brian Norton Appointed as CEO Following Tim Canning's Departure
TAMPA, FL, March 04, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ:WGRX) (the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that Tim Canning, Chief Executive Officer, will be departing the company. Mr. Canning's leadership tenure helped guide Wellgistics Health through pivotal phases, and the Company expresses gratitude for his contributions. Brian Norton has been officially appointed as Chief Executive Officer. Mr. Norton has a proven track record of success and expertise in healthcare, technology, and pharmaceutical supply chain innovation and has led high
3/4/25 5:18:00 PM ET
$WGRX
Other Pharmaceuticals
Health Care
Protega Pharmaceuticals collaborates with Wellgistics to support pharmacist education and increase patient access to the first and only FDA-approved abuse-deterrent immediate-release opioid, ROXYBOND™
ROXYBOND, formulated with patented, first-of-its-kind abuse-deterrent technology SentryBond™, is designed to provide multiple levels of protection Princeton, New Jersey, March 04, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ:WGRX, the ", Company", )), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that its wholly owned subsidiary, Wellgistics LLC, is collaborating with Protega Pharmaceuticals Inc. ("Protega"). Protega is the innovative specialty pharmaceutical company that launched ROXYBOND™ (oxycodone hydrochloride), the first and only FDA-approved abuse-deterrent imme
3/4/25 7:40:00 AM ET
$WGRX
Other Pharmaceuticals
Health Care
Wellgistics Expands Healthcare Ecosystem with Tollo Health Agreement, Targeting Multi-Billion Dollar GLP-1 and Long COVID Market
Tampa, Florida, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ:WGRX, the ", Company", )), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that its wholly owned subsidiary, Wellgistics LLC, has entered into an agreement with Tollo Health, LLC ("Tollo") to market Tollo's emerging proprietary suite of novel medical food products for GLP-1 treatment-related side effects, including muscle loss and Long COVID to pharmacies. Tollo is bringing to market novel, proprietary medical food products to address muscle loss and gut discomfort associated with GLP-1 drug use, and pe
2/26/25 7:40:00 AM ET
$WGRX
Other Pharmaceuticals
Health Care
Wellgistics Health, Inc. Announces Closing of $4.0 Million Initial Public Offering
Tampa, Florida, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced the closing of its initial public offering (the "Offering") of 888,889 shares of its common stock at a public offering price of $4.50 per share. The shares have been approved for listing on the Nasdaq Capital Market and commenced trading on February 21, 2025, under the ticker symbol "WGRX." The Company received $4.0 million in gross proceeds from the Offering, before deducting underwriting discounts and other related expenses. The Company intends
2/24/25 4:05:00 PM ET
$WGRX
Other Pharmaceuticals
Health Care

Wellgistics Health Inc.

Recent Analyst Ratings for Wellgistics Health Inc.

Wellgistics Health Inc.

Recent Analyst Ratings for Wellgistics Health Inc.

Wellgistics Health Inc. Press Releases

Fastest customizable press release news feed in the world

Wellgistics Health Annual Letter to Shareholders From the Office of the CEO March 2025

Wellgistics Health Achieves SOC 2 Type 1 Compliance, Strengthening Security for AI-Driven Pharmacy Solutions and Employer-Based Healthcare Models

Wellgistics Health, Inc. Announces Leadership Transition: Brian Norton Appointed as CEO Following Tim Canning's Departure

Protega Pharmaceuticals collaborates with Wellgistics to support pharmacist education and increase patient access to the first and only FDA-approved abuse-deterrent immediate-release opioid, ROXYBOND™

Wellgistics Expands Healthcare Ecosystem with Tollo Health Agreement, Targeting Multi-Billion Dollar GLP-1 and Long COVID Market

Wellgistics Health, Inc. Announces Closing of $4.0 Million Initial Public Offering

Wellgistics Health Inc. SEC Filings

Wellgistics Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits

Wellgistics Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

Wellgistics Health Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-K filed by Wellgistics Health Inc.

Wellgistics Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 424B3 filed by Wellgistics Health Inc.

Wellgistics Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

Wellgistics Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Wellgistics Health Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Wellgistics Health Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

New insider Kalla Srinivas claimed ownership of 293,333 shares (SEC Form 3)

SEC Form 3 filed by new insider Disiena Mark

Chief Clinical Officer Pirani Shafaat was granted 35,000 shares, increasing direct ownership by 52% to 102,080 units (SEC Form 4)

Director Syed Sajid was granted 200,000 shares, increasing direct ownership by 447% to 244,720 units (SEC Form 4)

Director Ajjarapu Surendra K was granted 4,082,247 shares (SEC Form 4)

Chief Strategy Officer Patel Prashant was granted 4,082,247 shares, increasing direct ownership by 84% to 4,118,247 units (SEC Form 4)

Director Anderson Donald William was granted 200,000 shares, increasing direct ownership by 447% to 244,720 units (SEC Form 4)

Chief Executive Officer Norton Brian was granted 9,000,000 shares, increasing direct ownership by 20,125% to 9,044,720 units (SEC Form 4)

Chief Pharmacy Officer Panchal Nikul was granted 90,000 shares (SEC Form 4)

Director Shanahan Rebecca M was granted 200,000 shares, increasing direct ownership by 447% to 244,720 units (SEC Form 4)